Alan K Oglesby (Alan Oglesby)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 11

Top Topics

Men Who Have Sex With Men

Antiretroviral Therapy

Hiv Infected Patients

Top Venues

Infectious diseases and therapy

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Stefan Schneider, Gary Blick, Christina Burke, Douglas Ward, Paul Benson, Franco Felizarta, Dallas Green, Cynthia Donovan, Gavin Harper, Deanna Merrill, Aimee A Metzner, Katie Mycock, Hannah Wallis, Jimena Patarroyo, Andrew P Brogan, Alan K Oglesby
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study. Infectious diseases and therapy 13 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Stefan Schneider, Gary Blick, Christina Burke, Douglas Ward, Paul Benson, Franco Felizarta, Dallas Green, Cynthia Donovan, Gavin Harper, Deanna Merrill, Aimee A Metzner, Katie Mycock, Hannah Wallis, Jimena Patarroyo, Andrew P Brogan, Alan K Oglesby
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study. Infectious diseases and therapy 13 (4) (2024)
Stefan Schneider, Gary Blick, Christina Burke, Douglas Ward, Paul Benson, Franco Felizarta, Dallas Green, Cynthia Donovan, Gavin Harper, Deanna Merrill, Aimee A Metzner, Katie Mycock, Hannah Wallis, Jimena Patarroyo, Andrew P Brogan, Alan K Oglesby
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study. Infectious diseases and therapy 13 (4) (2024)
Stefan Schneider, Gary Blick, Christina Burke, Douglas Ward, Paul Benson, Franco Felizarta, Dallas Green, Cynthia Donovan, Gavin Harper, Deanna Merrill, Aimee A Metzner, Katie Mycock, Hannah Wallis, Jimena Patarroyo, Andrew P Brogan, Alan K Oglesby
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study. Infectious diseases and therapy 13 (4) (2024)
Stefan Schneider, Gary Blick, Christina Burke, Douglas Ward, Paul Benson, Franco Felizarta, Dallas Green, Cynthia Donovan, Gavin Harper, Deanna Merrill, Aimee A Metzner, Katie Mycock, Hannah Wallis, Jimena Patarroyo, Andrew P Brogan, Alan K Oglesby
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study. Infectious diseases and therapy (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Stefan Schneider, Gary Blick, Christina Burke, Douglas Ward, Paul Benson, Franco Felizarta, Dallas Green, Cynthia Donovan, Gavin Harper, Deanna Merrill, Aimee A Metzner, Katie Mycock, Hannah Wallis, Jimena Patarroyo, Andrew P Brogan, Alan K Oglesby
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study. Infectious diseases and therapy 13 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics (2024)